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ABSTRACT 
Patients with glucocorticoid-remediable aldosteronism (GRA) pos- 
sess a chimeric gene resulting from fusion of the genes encoding steroid 
aldosterone synthase and ll&hydroxylase. In the adrenal zona fasci- 
culata, this may lead to ectopic expression under ACTH control of 
aldosterone synthase activity and increased formation of cortisol Cla 
oxidation products. We assessed mineralocorticoid and glucocorticoid 
pathways in three patients with GRA. Baseline plasma progesterone, 
17a-hydroxyprogesterone, corticosterone, and cortisol were normal in 
all patients, whereas Il-deoxycorticosterone, aldosterone, and ll-deox- 
ycortisol were above normal. The ratios of both corticosterone/ll- 
deoxycorticosterone and cortisol/ll-deoxycortisol were abnormally 
low, and decreased further 60 min after administration of ACTH-(l- 
24) (250 rg) as an iv bolus. A low corticosterone/ll-deoxycorticosterone 
ratio is consistent with an increased aldosterone synthase activity 
forming aldosterone by corticosterone. Similarly, a decreased cortisol/ 
11-deoxycortisol ratio could reflect enhanced cortisol Cla oxidation. 
Our findings are in agreement with a hyperfunction of the 11/3-hydrox- 
ylase/aldosterone synthase complex in the adrenal zona fasciculata of 
GRA induced by the new chimeric gene. (J Clin Endocrirwl Metab 79: 
772-774, 1994) 
G LUCOCORTICOID -remediable aldosteronism (GRA) is an ACTH-dependent autosomal dominant form of 
mineralocorticoid hypertension in which the excessive aldos- 
terone production and clinical syndrome are corrected by the 
administration of glucocorticoids (1, 2). The genetic abnor- 
mality has recently been described (3,4); the mutation results 
from fusion of the genes encoding steroid 11/3-hydroxylase 
and aldosterone synthase. In the adrenal zona fasciculata, 
this may lead to ectopic expression under ACTH control of 
aldosterone synthase activity, which normally catalizes both 
corticosterone and l%hydroxycorticosterone methyl oxida- 
tions in the zona glomerulosa. A specific biochemical abnor- 
mality of this disease is, in fact, the overproduction of cortisol 
Cl8 oxidation metabolites (5-7). Scattered data are available 
on precursor steroids of aldosterone and cortisol in this 
disease. In particular, whereas aldosterone precursors are 
reported variably high (g-10) or normal (11, 12), cortisol 
precursors have been found in the normal range (7, 13). We 
studied three patients with GRA, assessing mineralocorticoid 
and glucocorticoid pathways both under baseline conditions 
and after ACTH stimulation. 
Subjects and Methods 
Three siblings (patient 1, female, aged 19 yr; and patients 2 and 3, 
males, aged 23 and 35 yr, respectively) in a family of nine siblings were 
shown to have GRA. The family pedigree and a detailed biochemical 
and hormonal assessment of all family members have been previously 
reported (14). The chimeric bands analyzed by Southern blot in leuko- 
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cyte DNA indicating the genetic abnormality in patients 1 and 2 have 
been reported previously (15), whereas in patient 3 this genetic study 
was not performed. Hormonal evaluation was conducted under baseline 
conditions before glucocorticoid treatment while patients received a 
normal sodium (150 mmol/day) and potassium (60 mmol/day) diet. All 
three patients were hypertensive and hypokalemic at the time of the 
study. Urinary sodium excretion was 136, 142, and 140 mmol/day in 
patients 1, 2, and 3, and urinary potassium excretion was 74, 66, and 
70 mmol/day in patients 1,2, and 3, respectively. As previously reported 
(16), urinary products of cortisol Cl8 oxidation 18-oxocortisol (as the 
tetrahydro derivative) and 18-hydroxycortisol, measured by gas chro- 
matography-mass spectrometry, were very high (18-oxotetrahydrocor- 
tisol: 154,356, and 608 nmol/hay; normalmean rt SD, 7 + 5 nmol/day; 
18-hvdroxvcortisol, 1048, 2768, and 2943 nmol/dav; normal. 110 + 60 
,  2 
nmol/day in patients 1, 2, and 3, respectively). Plasma levels of proges- 
terone, 11-deoxycorticosterone, corticosterone, aldosterone, l’la-hy- 
droxyprogesterone, 11 -deoxycortisol, and cortisol were measured at 
0900 h after a 30-min rest in an armchair, before and 60 min after 
ACTH-(l-24) adminiitration (Synacthen, Ciba, Basel, Switzerland; 250 
pg as an iv bolus). Four unaffected siblings of the family underwent the 
same hormonal evaluation. Twenty healthy subjects (10 males and 10 
females, aged 17-44 yr) were used as normal controls. All plasma 
steroids were measured by the method of Sippell et al. (17), using 
mechanized Sephadex LH-20 multiple column chromatography and 
specific RIAs. For normal values, see Table 1. 
Results 
Plasma steroid results are reported in Table 1. Baseline 
progesterone, corticosterone, 17a-hydroxyprogesterone, and 
cortisol levels were normal in all three patients and re- 
sponded normally to ACTH standard stimulation test. Base- 
line and ACTH-stimulated 11 -deoxycorticosterone, aldoster- 
one, and 1 I-deoxycortisol levels were above normal. Both 
baseline corticosterone/l 1-deoxycorticosterone and cortisol/ 
ll-deoxycortisol ratios, expressed on an equimolar basis, 
were abnormally low [24, 19, and 12 (normal range, 46-78) 
and 17, 13, and 12 (normal range, 15%210), respectively] 
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TABLE 1. Plasma steroid levels in the three patients with GRA and normal controls before and after ACTH treatment 
P (nmol/L) 
DOC 
(nmol/L) 
B (nmol/L) 
ALDO 17-OHP 
(pmol/L) (nmol/L) 
s (nmol/L) F (nmol/L) 
Patient 1 
Baseline 0.58 0.37 9.02 416.8 2.3 13.2 221.2 
ACTH 2.49 4.55 87.1 1156 7.0 43.1 594.0 
Patient 2 
Baseline 0.66 0.46 8.82 341.2 3.7 14.1 181.8 
ACTH 2.27 5.72 47.9 890.2 11.0 78.3 380.7 
Patient 3 
Baseline 0.28 0.37 4.46 205.4 2.6 14.5 178.8 
ACTH 1.80 5.22 52.4 818.3 8.7 77.7 525.0 
Normal subjects (n = 20) 
Baseline 0.45 + 0.3 0.13 + 0.04 8.42 _t 5.1 124.2 + 27 2.4 + 0.8 1.65 f  0.7 281.4 + 99 
ACTH 1.51 * 0.5 1.54 + 0.27 97.4 + 36.2 196.8 z!z 66 6.4 zk 2.1 6.7 -e 1.5 842.8 + 151 
P, Progesterone; DOC, ll-deoxycorticosterone; B, corticosterone; ALDO, aldosterone; 17-OHP, 17a-hydroxyprogesterone; S, ll-deoxycortisol; 
F, cortisol. 
and decreased further after ACTH-(1-24) administration [19, 
8, and 10 (normal range, 52-84) and 14, 5, and 7 (normal 
range, 104-153), respectively]. Four unaffected siblings of 
the family showed no steroid abnormalities either under 
baseline conditions or after ACTH stimulation (data not 
shown). 
Discussion 
Recently, fusion genes generated by unequal cross-over 
were identified as the underlying cause of GRA in 16 
kindreds, including ours (15). The gene is a hybrid with a 
5’-regulatory ACTH-responsive region of the gene encoding 
for isoenzyme CYPl lB1 (P45Ocl l), which mediates the last 
step of cortisol synthesis, lip-hydroxylation, and the 3’- 
coding region of the gene encoding for isozyme CYPllB2 
(P450aldo synthase), which mediates the final three steps of 
aldosterone synthesis, lip- and 18-hydroxylation, and 18- 
oxidation (3, 4, 18). These two P450 enzymes are normally 
encoded by twin genes on chromosome 8 and share greater 
than 90% homology (19). The biochemical consequence of 
the genetic rearrangement in GRA is the formation of aldos- 
terone under ACTH drive by the zona fasciculata, together 
with 18-hydroxy- and 18-oxocortisol formation from the 
methyl oxidation of cortisol. Interestingly, both baseline and 
ACTH-stimulated 11-deoxycorticosterone and 1 l-deoxycor- 
tisol were above normal in our cases, suggesting hyperre- 
sponsivity of the zona fasciculata to ACTH, involving mul- 
tiple steroidogenic steps. Overproduction of sodium-retain- 
ing steroids other than aldosterone has been advocated to 
explain the dramatic effect of increasing blood pressure in 
these patients after prolonged ACTH administration (20). 
However, due to abnormal adrenal zonation, it is not possible 
to separate mineralocorticoid and glucocorticoid pathways in 
the absence of glucocorticoid treatment. 
The ratios of plasma concentrations of corticosterone to 
11 -deoxycorticosterone and cortisol to 11 -deoxycortisol are 
considered an indirect assessment of 1 l&hydroxylase activ- 
ity (21), i.e. increased function of this enzyme corresponds 
to decreased ratios due to enhanced formation of end prod- 
ucts. Accordingly, both of these ratios were below normal in 
our patients, in whom an accelerated metabolism of corticos- 
terone and cortisol, due to abnormal sensitivity of lip- 
hydroxylase/aldosterone synthase to endogenous ACTH, oc- 
curred. Moreover, exogenous ACTH administration further 
lowered both corticosterone/l 1-deoxycorticosterone and cor- 
tisol/l 1-deoxycortisol ratios, confirming the marked ACTH 
dependence of cortisol metabolites (22) and aldosterone (14, 
23) as a typical feature of GRA. In conclusion, our data are 
in agreement with a hyperfunction of the lib-hydroxylasel 
aldosterone synthase complex in the adrenal zona fasciculata 
induced by the new chimaeric gene in this disorder. 
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